Ackermann Michael
Known title: DirectorCIK: 0001791249
Ackermann Michael's purchase track record
Ackermann Michael has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/5/2022 | TARS | $1.35M | +42.3% | +48.9% | -10.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TARS | ▲ Buy | Option Exercise | 4,257 | — | 6/15/2022 | View on chart |
| TARS | ▲ Buy | Open Market | 100,000 | $1.4M | 5/5/2022 | View on chart |
| TARS | ▼ Sell | Open Market | 2,442 | $58K | 12/1/2021 | View on chart |
| TARS | ▼ Sell | Open Market | 2,054 | $51K | 12/1/2021 | View on chart |
| TARS | ▼ Sell | Open Market | 809 | $21K | 12/1/2021 | View on chart |
| TARS | ▼ Sell | Open Market | 528 | $14K | 12/1/2021 | View on chart |
| TARS | ▼ Sell | Open Market | 4,964 | $138K | 11/1/2021 | View on chart |
| TARS | ▼ Sell | Open Market | 869 | $24K | 11/1/2021 | View on chart |
| TARS | ▼ Sell | Open Market | 1,116 | $29K | 10/12/2021 | View on chart |
| TARS | ▼ Sell | Open Market | 4,517 | $119K | 10/12/2021 | View on chart |
| TARS | ▼ Sell | Open Market | 200 | $5K | 10/8/2021 | View on chart |
| TARS | ▼ Sell | Open Market | 5,833 | $147K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals
The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.